載入中
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
前收盤價
US$4.65
+US$0.19 · +4.26%
盤中時間採用ET。市場資料可能有所延遲。
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
日內區間
目前US$4.65
52週區間
目前US$4.65
盤中時間採用ET。市場資料可能有所延遲。
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
日內區間
目前US$4.65
52週區間
目前US$4.65
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1419.6萬 USD | 1099.2萬 USD | 1904.9萬 USD | 3985萬 USD | 58.9萬 USD |
| 毛利 | 1419.6萬 USD | 1099.2萬 USD | 1904.9萬 USD | 3985萬 USD | 58.9萬 USD |
| 研究與開發 | 3081.2萬 USD | 2685.1萬 USD | 1765.3萬 USD | 1435.5萬 USD | 1517.3萬 USD |
| 銷售、一般及管理費用 | 2198.3萬 USD | 1821.5萬 USD | 1195.9萬 USD | 726.9萬 USD | 812.1萬 USD |
| 營業費用 | 5279.5萬 USD | 7306.6萬 USD | 2961.2萬 USD | 2162.4萬 USD | 2329.4萬 USD |
| 利息支出 | 146.6萬 USD | — | 132.8萬 USD | 9000 USD | 2000 USD |
| 折舊和攤銷 | 5.3萬 USD | 1萬 USD | 6000 USD | 4000 USD | 4000 USD |
| 營業利益 | −3859.9萬 USD | −6207.4萬 USD | −1056.3萬 USD | 1822.6萬 USD | −2270.5萬 USD |
| 淨利 | −4959.1萬 USD | −5753.2萬 USD | −998.6萬 USD | 1788.8萬 USD | −5669.3萬 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
iShares Russell 2000 ETFIWM812.33萬0.01%787.4億 USD0.19%US$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI810.66萬0.00%2.3兆 USD0.03%US$381.94+0.63%
iShares Russell 2000 Growth ETFIWO283.55萬0.02%139.17億 USD0.24%US$356.78+0.94%
Vanguard Extended Market ETFVXF236.12萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Russell 2000 ETFVTWO111.68萬0.01%180億 USD0.06%US$112.66+0.50%
iShares Micro-Cap ETFIWC98.39萬0.07%13.17億 USD0.60%US$183+0.11%
Goldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSC41.34萬0.04%10.45億 USD0.20%US$86.29+0.43%
Fidelity Enhanced Small Cap ETFFESM38.16萬0.01%64.1億 USD0.28%US$45.46+0.46%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFGSSCFidelity Enhanced Small Cap ETFFESMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
